Selvita S.A.
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational re… Read more
Selvita S.A. (SLV) - Net Assets
Latest net assets as of September 2025: zł316.29 Million PLN
Based on the latest financial reports, Selvita S.A. (SLV) has net assets worth zł316.29 Million PLN as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł610.80 Million) and total liabilities (zł294.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł316.29 Million |
| % of Total Assets | 51.78% |
| Annual Growth Rate | 23.86% |
| 5-Year Change | 110.85% |
| 10-Year Change | N/A |
| Growth Volatility | 68.53 |
Selvita S.A. - Net Assets Trend (2015–2024)
This chart illustrates how Selvita S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Selvita S.A. (2015–2024)
The table below shows the annual net assets of Selvita S.A. from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł321.88 Million | -1.59% |
| 2023-12-31 | zł327.07 Million | +19.74% |
| 2022-12-31 | zł273.16 Million | +32.89% |
| 2021-12-31 | zł205.55 Million | +34.65% |
| 2020-12-31 | zł152.66 Million | +220.33% |
| 2019-12-31 | zł47.66 Million | -3.11% |
| 2018-12-31 | zł49.19 Million | +31.73% |
| 2017-12-31 | zł37.34 Million | -32.97% |
| 2016-12-31 | zł55.71 Million | +18.84% |
| 2015-12-31 | zł46.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Selvita S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3711.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | zł132.60 Million | 41.20% |
| Common Stock | zł14.68 Million | 4.56% |
| Other Comprehensive Income | zł88.14 Million | 27.38% |
| Other Components | zł86.45 Million | 26.86% |
| Total Equity | zł321.88 Million | 100.00% |
Selvita S.A. Competitors by Market Cap
The table below lists competitors of Selvita S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Duos Technologies Group Inc
NASDAQ:DUOT
|
$127.03 Million |
|
Balaji Amines Limited
NSE:BALAMINES
|
$127.06 Million |
|
Archer Limited
PINK:ARHVF
|
$127.09 Million |
|
Jikai Equipment Manufacturing Co Ltd
SHE:002691
|
$127.11 Million |
|
Hansa Biopharma AB
ST:HNSA
|
$127.01 Million |
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
$126.98 Million |
|
Avita Medical Ltd
NASDAQ:RCEL
|
$126.88 Million |
|
Nabors Energy Transition Corp. II Class A Ordinary Shares
NASDAQ:NETD
|
$126.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Selvita S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 327,071,000 to 321,877,000, a change of -5,194,000 (-1.6%).
- Net loss of 6,098,000 reduced equity.
- Other comprehensive income increased equity by 904,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-6.10 Million | -1.89% |
| Other Comprehensive Income | zł904.00K | +0.28% |
| Total Change | zł- | -1.59% |
Book Value vs Market Value Analysis
This analysis compares Selvita S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.82x to 2.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | zł2.89 | zł37.00 | x |
| 2016-12-31 | zł3.44 | zł37.00 | x |
| 2017-12-31 | zł2.21 | zł37.00 | x |
| 2018-12-31 | zł2.87 | zł37.00 | x |
| 2019-12-31 | zł2.77 | zł37.00 | x |
| 2020-12-31 | zł8.56 | zł37.00 | x |
| 2021-12-31 | zł10.73 | zł37.00 | x |
| 2022-12-31 | zł14.28 | zł37.00 | x |
| 2023-12-31 | zł17.82 | zł37.00 | x |
| 2024-12-31 | zł17.54 | zł37.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Selvita S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.78%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.99x
- Recent ROE (-1.89%) is below the historical average (11.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 13.50% | 15.28% | 0.63x | 1.40x | zł1.63 Million |
| 2016 | 4.91% | 5.65% | 0.54x | 1.61x | zł-2.82 Million |
| 2017 | 11.01% | 7.19% | 1.14x | 1.34x | zł361.58K |
| 2018 | 22.70% | 14.85% | 0.97x | 1.57x | zł5.87 Million |
| 2019 | 12.49% | 18.14% | 0.33x | 2.06x | zł1.10 Million |
| 2020 | 12.22% | 13.10% | 0.63x | 1.49x | zł3.27 Million |
| 2021 | 7.57% | 4.79% | 0.67x | 2.37x | zł-4.79 Million |
| 2022 | 11.56% | 8.40% | 0.62x | 2.23x | zł4.09 Million |
| 2023 | 21.36% | 20.15% | 0.54x | 1.95x | zł37.17 Million |
| 2024 | -1.89% | -1.78% | 0.53x | 1.99x | zł-38.29 Million |
Industry Comparison
This section compares Selvita S.A.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $95,578,023
- Average return on equity (ROE) among peers: 8.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Selvita S.A. (SLV) | zł316.29 Million | 13.50% | 0.93x | $127.03 Million |
| Biomaxima (BMX) | $25.94 Million | 30.64% | 1.06x | $7.70 Million |
| Scope Fluidics SA (SCP) | $16.88 Million | -24.72% | 0.11x | $52.03 Million |
| Voxel S.A. (VOX) | $243.91 Million | 18.21% | 0.92x | $143.97 Million |